Xilio Therapeutics (XLO) Current Leases (2020 - 2026)

Xilio Therapeutics has disclosed Current Leases across 7 years of filings, most recently posting $1.4 million for Q1 2026.

• Current Leases for Q1 2026 came in at $1.4 million, up 12.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 million (up 12.89% YoY), and the FY2025 annual result was $1.3 million, up 13.05% from the prior year.
• Current Leases came in at $1.4 million for Q1 2026 at Xilio Therapeutics, up from $1.3 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $1.4 million in Q1 2026 to a low of $829000.0 in Q1 2022.
• The 5-year median for Current Leases is $1.1 million (2024), against an average of $1.1 million.
• Across the five-year window, Current Leases climbed 14.88% in 2022 and gained 12.89% in 2026, its largest moves.
• Xilio Therapeutics' Current Leases stood at $918000.0 in 2022, then grew by 14.05% to $1.0 million in 2023, then increased by 13.47% to $1.2 million in 2024, then advanced by 13.05% to $1.3 million in 2025, then grew by 3.05% to $1.4 million in 2026.
• The last three Current Leases figures came in at $1.4 million (Q1 2026), $1.3 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.